North America Life Science Tools Market Size, Share & Trends Analysis Report By End-use, By Technology (Cell Biology, Proteomics Technologies), By Product (PCR & qPCR, Cell Biology), And Segment Forecasts, 2020 - 2027

Report Overview

The North America life science tools market size was valued at USD 33.8 billion in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 11.6% from 2020 to 2027. Increased government funding for life science technologies is expected to drive the market at a significant rate. Organizations, such as The National Human Genome Research Institute (NHGRI) and the National Institutes of Health (NIH), are actively funding multiple life science projects. The NHGRI collaborates with researchers and scientists to provide funds for genomic research, such as identification of the genomic basis of human diseases, and health; and understand the complexities associated with the human genome. NHGRI is working toward the application of genomic technologies to enhance patient care and benefit society.

The Glycoscience Program, 4D Nucleome Program, and Gabriella Miller Kids First Pediatric Research Program are the NIH common fund awards for biomedical research. During the Covid-19 pandemic, the U.S. FDA granted Emergency Use Authorizations (EUAs) to several diagnostic tests to make them rapidly and easily available for use. The FDA has issued EUAs to various types of Covid-19 tests, such as PCR-based molecular tests and serological & antigen tests. Thermo Fisher announced in March 2020 to develop up to 5 million Covid-19 test kits.

Moreover, in May 2020, the company stated that the FDA expanded the EUA for the company’s real-time PCR test, which detects nucleic acid from SARS‑CoV‑2. This approval expanded the application of the TaqPath Covid-19 Combo Kit developed by Thermo Fisher along with Applied Biosystems’ 7500 Real-time PCR series system. Likewise, in June 2020, Biocept, Inc. stated the availability of 10,000 nasopharyngeal specimen collection kits that provide RT-PCR-based testing for Covid-19.

In addition to PCR, several other nucleic acid assays, such as isothermal amplification assays, amplicon-based metagenomics sequencing, hybridization microarray assays, and CRISPR-related technologies, are also gaining momentum in the marketplace. The number of FDA EUA-approved tests is constantly increasing with a number of tests under development.

For instance, in August 2020, Oxford Nanopore introduced LamPORE, a portable test designed for the detection of Covid-19 and other seasonal flu viruses from saliva or swab samples within an hour. This test is based on the Loop-Mediated Isothermal Amplification (LAMP), a DNA amplification technology that only requires one incubation temperature, simple machinery, and provides faster results than PCR. Such initiatives are expected to drive market growth.

Technology Insights

Cell biology technology dominated the market in 2019 and accounted for the largest revenue share of over 33%. The segment will expand further at a significant CAGR from 2020 to 2027. The relevance of cell biology technology in drug discovery and the rise in NIH/NSF funding for cell biology can be attributed to the segment’s steady growth.

In addition, advancements in liquid handling and flow cytometry have led to a dramatic rise in the applications of cell-based assays for drug discovery. Moreover, late-stage failure of pre-clinical animal models during drug discovery further increases the adoption of cell-based assays as they offer a practical alternative by predicting in vivo activities of novel drug candidates. Mass spectrometry is a key technique employed throughout the proteomic workflows.

Thus, technological advancements in mass spectrometry drive proteomic discovery capabilities. Development of high-mass accuracy, high-resolution mass spectrometers, such as Orbitrap and time-of-flight (TOF) mass analyzers have improved the identification of posttranslational modifications, and peptides. Enhancement of mass resolution has led to an increase in the overall mass range, thereby leading toward efficient analysis.

Product Insights

The cell biology product segment led the global market in 2019 with a revenue share of over 19%. Researchers in the life science industry are keen on adopting modern instruments, which is expected to drive the segment growth. This trend has encouraged several manufacturers to expand their cell biology instrument portfolios. For instance, Cytiva, Horizon Discovery, BioTek Instruments, and Seahorse Bioscience, are focusing on developing instruments pertaining to cell biology, analysis, and imaging.

Each of the cell biology applications demands specific sets of protocols, techniques, and lab instruments. Early developments in this segment have offered scientists with significant insights, further encouraging the development of confocal scanning microscopy and electron microscopy, making them mainstream instruments. Recent trends in the life science tools industry have propelled technological interventions aimed at advancing drug research.

The integration of smart technology has enhanced the efficiency of patient assessment, fueling the demand for separation technologies, Next-Generation Sequencing (NGS), and PCR. In addition, the development of integrated devices, such as MRI scans, in-patient monitoring & management tools, and laboratory equipment, is aiding in improved assessment & management of patients, which is expected to propel the market.

Through these integrated devices, healthcare professionals can process the data required to prescribe the right medications to patients. Collaborations between several industry stakeholders have significantly driven innovations in this field, encouraging emerging entities to invest in the development of modern life science tools. In addition, the advent of modern tools, such as bi-specific antibodies, nanosensors, and computational biology, has prompted further collaborations between manufacturing entities across a range of disciplines, including flow cytometry, mass spectrometry, and nucleic acid microarray.

End-use Insights

Healthcare dominated the end-use segment in 2019 with a revenue share of over 33%. The segment will expand further at the fastest CAGR from 2020 to 2027 as several hospitals and clinics are currently offering sequencing services to patients and are determining the use of this technology in the daily practice of medicine. Stanford Medicine is one such hospital that offers sequencing service to individuals who have a rare or undiagnosed condition that is believed to be genetic.

Partners HealthCare in the U.S. is one of the first hospital systems to provide genomic sequencing, analysis, and interpretation services to the public. It has enrolled over 200 patients and physicians in a study funded by NIH to study the integration of whole-genome sequencing in clinical medicine. The industrial sector includes applied applications of life science tools within the bioengineering and applied biosciences fields.

The market is marked by multi-disciplinary research within the biological engineering, and novel biosciences domains. The segment is inclusive of biochemical engineering, pharmaceutical engineering, and other applied sciences. Proteomics technology has been used in drug discovery, development, neuroscience, apoptosis, and toxicology analysis. The knowledge of proteomics science has been applied in the food industry to characterize and map changes in the protein components present in foods during production.

Regional Insights

The U.S. dominated the market in North America in 2019 with a revenue share of over 89%. The application of life sciences tools in disease diagnosis is anticipated to propel the U.S. market. For instance, in June 2020, the FDA issued an emergency use authorization for COVIDSeq Test; an NGS-based Covid-19 diagnostic test developed by Illumina. Owing to the use of NGS, the viral genomic sequence obtained from samples can be used for research to understand the mutation patterns of the virus.

The U.S. has been a host to several conferences and seminars pertaining to life science research. These events keep the researchers updated with the latest technologies and, thereby, increase the adoption of life science tools. The American Society for Mass Spectrometry has planned to organize the 69th ASMS Conference on Mass Spectrometry and Allied Topics in June 2021 in Philadelphia. Such initiatives are anticipated to increase revenue generation in the U.S. life science tools market.

An increase in R&D in biotechnology due to growing funding by the Canadian government has led to increased demand for life science tools, thus boosting the market growth in the country. In October 2020, the Canadian government announced to invest USD 6.5 million for Toronto Innovation Acceleration Partners (TIAP). TIAP is a membership-based organization of research hospitals, institutions, and top universities in Canada that work to improve and advance various health science technologies.

Key Companies & Market Share Insights

Most of the market players are involved in the development and launch of novel products to increase their market presence. For instance, in September 2020, Thermo Fisher introduced the latest collection of Thermo Scientific Tox Explorer product line, which includes comprehensive LC-MS workstream products suitable for toxicology assay applications. This product line also comprises a comprehensive analyte library, which enables rapid identification as well as targeted assay screening, with the ability to confirm the presence of more than 1,000 compounds in a single analysis. Some of the prominent companies in the North America life science tools market include:

• Thermo Fisher Scientific, Inc.

• F. Hoffmann-La Roche Ltd.

• Illumina, Inc.

• Agilent Technologies

• Becton, Dickinson and Company (BD)

• Bio-Rad Laboratories, Inc.

• Danaher Corporation

• General Electric Company

• Merck KGaA

• QIAGEN

• Corning, Inc.

• Perkin Elmer, Inc.

• Miltenyi Biotec

• Bruker

• Hitachi Koki Co., Ltd.

• Shimadzu Corporation

• Oxford Instruments

North America Life Science Tools Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2027. For the purpose of this study, Grand View Research has segmented the North America life science tools market report on the basis of technology, product, end-use, and country:

• Technology Outlook (Revenue, USD Million, 2016 - 2027)

  • Genomic Technology

  • Proteomics Technology

  • Cell Biology Technology

  • Other Analytical & Sample Preparation Technology

  • Lab Supplies & Technologies

• Product Outlook (Revenue, USD Million, 2016 - 2027)

  • Next-Generation Sequencing

    • Instrument

    • Consumables

    • Services

  • PCR & qPCR

    • Instrument

    • Consumables

    • Services

  • Flow Cytometry

    • Instrument

    • Consumables

    • Services

  • Nuclear Magnetic Resonance Spectroscopy (NMR)

    • Instrument

    • Consumables

    • Services

  • Microscopy & Electron Microscopy

    • Instrument

    • Consumables

    • Services

  • Liquid Chromatography (LC)

    • Instrument

    • Consumables

    • Services

  • Mass Spectrometry (MS)

    • Instrument

    • Consumables

    • Services

  • Nucleic Acid Preparation (NAP)

    • Instrument

    • Consumables

    • Services

  • Transfection Electroporation

    • Equipment

    • Reagents

  • Cell Biology

    • Instrument

      • Glassware

      • Culture ware

      • Others

    • Consumables

      • Media & Sera

      • Reagents

    • Cell & Tissue Culture Services

  • Cloning

    • Kits, Reagents, and Consumables

    • Services

  • Other Products & Services

    • Antibodies

    • General Supplies

    • Nucleic Acid Microarray

      • Instrument

      • Consumables

      • Services

    • Others

      • Instrument

      • Consumables

      • Services

• End-use Outlook (Revenue, USD Million, 2016 - 2027)

  • Government & Academic

  • Biopharmaceutical Company

  • Healthcare

  • Industrial Application

  • Others

• Country Outlook (Revenue, USD Million, 2016 - 2027)

  • U.S.

  • Canada